Rifampicin Nanoformulation Enhances Treatment of Tuberculosis in Zebrafish.

Area of Science:

• Nanomedicine
• Infectious Diseases
• Materials Science

Background:

• Tuberculosis (TB) is caused by Mycobacterium tuberculosis, an intracellular pathogen residing in alveolar macrophages.
• Macrophages readily internalize nanoparticles, making nanotherapeutics a promising strategy for TB treatment.
• Rifampicin is a key drug in TB therapy, but its efficacy can be limited by delivery challenges.

Purpose of the Study:

• To develop and characterize methoxy poly(ethylene oxide)-block-poly(ε-caprolactone) nanoparticles as drug carriers for rifampicin.
• To evaluate the nanoparticles' physicochemical properties, cellular uptake, intracellular degradation, and efficacy against Mycobacterium tuberculosis.
• To assess the in vivo safety and therapeutic effect of these nanotherapeutics in a zebrafish model of TB.

Main Methods:

• Synthesis and characterization of methoxy poly(ethylene oxide)-block-poly(ε-caprolactone) nanoparticles with varying molecular weights and sizes (20-110 nm).
• In vitro studies on macrophage uptake, organelle targeting, and intracellular degradation kinetics of nanoparticles.
• In vitro assessment of nanoparticle efficacy in neutralizing Mycobacterium tuberculosis within macrophages.
• In vivo evaluation of nanoparticle tolerability and therapeutic effect in a zebrafish model of tuberculosis.

Main Results:

• Nanoparticle uptake and degradation rates were significantly influenced by their physicochemical properties.
• Macrophages efficiently internalized the nanoparticles, which effectively neutralized intracellular Mycobacterium tuberculosis.
• In a zebrafish model, the nanotherapeutics demonstrated a curative effect and were well tolerated.
• The nanoparticles showed significantly higher efficiency compared to free rifampicin in vivo.

Conclusions:

• Methoxy poly(ethylene oxide)-block-poly(ε-caprolactone) nanoparticles are effective carriers for rifampicin delivery in tuberculosis treatment.
• The nanoparticles' properties can be tuned to optimize cellular uptake and intracellular drug release.
• This nanotherapeutic system shows significant promise for both in vitro and in vivo treatment of tuberculosis.